RHO and neoplasm: Given that treatment with the ROCK inhibitor Y-27632 prevents anoikis [13], tumor cells harboring the ROCK1 nonsense mutation might be resistant to anoikis through the impairment of the Rho-ROCK pathway, similar to tumor cells harboring the RHOA L57V mutation.